661810login-checkCareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference |
April 25, 2023
Posters and Symposium Highlight Utility of AlloSeq for HLA Typing, Organ Transplant Monitoring and Hematopoietic Stem Cell Monitoring
BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase the latest developments across its AlloSeq®* portfolioduring the 36th European Immunogenetics and Histocompatibility Conference taking place April 26-29 in Nantes, France.
Read the complete press release on CareDx.com.
661810login-checkCareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference |